Are you motivated to participate in a dynamic, multi-tasking environment? Do you want to become part of a company that invests in its employees? Are you seeking a position where you use your laboratory skills while continuing to learn? Then we encourage you to dive deeper into this opportunity.
We believe in career development and empowering our employees. Not only do we provide career coaches internally, but we offer many training opportunities to expand your knowledge base! We have highly competitive benefits with a variety HMO and PPO options. We have company 401k match along with an Employee Stock Purchase Program. We have tuition reimbursement, leadership development, and even start employees off with 16 days of paid time off plus holidays. We offer wellness courses and have highly engaged employee resource groups. Come join the Neo team and be part of our amazing World Class Culture!
NeoGenomics is looking for a Clinical Laboratory Technologist to join our Molecular team at our lab in Aliso Viejo, CA who wants to continue to learn and grow.
Shift time: Tuesday-Saturday, 5:00pm-1:30am or 7:00pm-3:30am
Now that you know what we're looking for in talent, let us tell you why you'd want to work at NeoGenomics:
As an employer, we promise to provide you with a purpose driven mission in which you have the opportunity to save lives by improving patient care through the exceptional work you perform. Together, we will become the world's leading cancer reference laboratory.
Position Summary:
As a Clinical Laboratory Technologist, Molecular you will work under general supervision. You will be responsible for performing highly complex laboratory testing procedures and leading complex laboratory validations. You will figure out acceptability of specimens for testing, prepare clinical specimens and identify specimen related problems.
Responsibilities:
Experience, Education and Qualifications:
NeoGenomics, headquartered in Fort Meyers, Florida, is a company that specializes in cancer diagnostics and pharma services.
37 jobsSubscribe to Rise newsletter